Literature DB >> 27016106

National patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy.

Serge C Harb1, Muhammad Haq2, Kathleen Flood3, Angela Guerrieri3, Wendy Passerell3, Wael A Jaber4, Edward J Miller5.   

Abstract

BACKGROUND: Tc99m-pyrophosphate (Tc99m-PYP) scintigraphy has emerged as a diagnostic modality for transthyretin (TTR) cardiac amyloidosis (CA). We sought to examine the variability in test utilization across multiple centers in the US.
METHODS: An electronic, web-based survey addressing specifics on Tc-99m PYP imaging was emailed to ASNC members, totaling 2785 recipients. Only one response per institution was allowed.
RESULTS: Responses were collected from 101 centers between July 2 and July 27, 2015. Among the respondents, 24% performed Tc-99m PYP specifically for CA diagnosis. The most commonly used dose was 20 mCi (37%) and most centers (35%) imaged 1 hour after injection. Scans were most often interpreted by cardiologists (60%). Quantification of uptake was performed in 57% of institutions with almost half (43%) utilizing the heart-to-contralateral lung (H/CL) ratio.
CONCLUSIONS: This national survey shows relatively low penetrance and high variability in Tc99m-PYP scintigraphy for CA diagnosis highlighting the need for standardization.

Entities:  

Keywords:  National survey; Tc99m-pyrophosphate; cardiac amyloidosis

Mesh:

Substances:

Year:  2016        PMID: 27016106     DOI: 10.1007/s12350-016-0478-3

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  7 in total

1.  Revised transthyretin Ile 122 allele frequency in African-Americans.

Authors:  D R Jacobson; R Pastore; S Pool; S Malendowicz; I Kane; A Shivji; S H Embury; S K Ballas; J N Buxbaum
Journal:  Hum Genet       Date:  1996-08       Impact factor: 4.132

2.  Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.

Authors:  Claudio Rapezzi; Candida C Quarta; Pier Luigi Guidalotti; Cinzia Pettinato; Stefano Fanti; Ornella Leone; Alessandra Ferlini; Simone Longhi; Massimiliano Lorenzini; Letizia Bacchi Reggiani; Christian Gagliardi; Pamela Gallo; Caterina Villani; Fabrizio Salvi
Journal:  JACC Cardiovasc Imaging       Date:  2011-06

3.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.

Authors:  Enrica Perugini; Pier Luigi Guidalotti; Fabrizio Salvi; Robin M T Cooke; Cinzia Pettinato; Letizia Riva; Ornella Leone; Mohsen Farsad; Paolo Ciliberti; Letizia Bacchi-Reggiani; Francesco Fallani; Angelo Branzi; Claudio Rapezzi
Journal:  J Am Coll Cardiol       Date:  2005-09-20       Impact factor: 24.094

4.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.

Authors:  Esther González-López; Maria Gallego-Delgado; Gonzalo Guzzo-Merello; F Javier de Haro-Del Moral; Marta Cobo-Marcos; Carolina Robles; Belén Bornstein; Clara Salas; Enrique Lara-Pezzi; Luis Alonso-Pulpon; Pablo Garcia-Pavia
Journal:  Eur Heart J       Date:  2015-07-28       Impact factor: 29.983

5.  (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.

Authors:  Sabahat Bokhari; Adam Castaño; Ted Pozniakoff; Susan Deslisle; Farhana Latif; Mathew S Maurer
Journal:  Circ Cardiovasc Imaging       Date:  2013-02-11       Impact factor: 7.792

6.  Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.

Authors:  Selma F Mohammed; Sultan A Mirzoyev; William D Edwards; Ahmet Dogan; Donna R Grogan; Shannon M Dunlay; Veronique L Roger; Morie A Gertz; Angela Dispenzieri; Steven R Zeldenrust; Margaret M Redfield
Journal:  JACC Heart Fail       Date:  2014-04       Impact factor: 12.035

Review 7.  Transthyretin (TTR) cardiac amyloidosis.

Authors:  Frederick L Ruberg; John L Berk
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

  7 in total
  12 in total

Review 1.  Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction.

Authors:  Wengen Chen; Van-Khue Ton; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2018-03-08       Impact factor: 2.931

2.  Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis.

Authors:  Yong Joong Kim; Sejin Ha; Yong-Il Kim
Journal:  J Nucl Cardiol       Date:  2018-07-18       Impact factor: 5.952

Review 3.  Recent advances in the noninvasive strategies of cardiac amyloidosis.

Authors:  Lei Zhao; Quan Fang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

4.  Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: Associations with echocardiographic disease severity and outcomes.

Authors:  Michael N Vranian; Brett W Sperry; Mazen Hanna; Rory Hachamovitch; Asad Ikram; Richard C Brunken; Wael A Jaber
Journal:  J Nucl Cardiol       Date:  2017-01-03       Impact factor: 5.952

5.  Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis.

Authors:  Ahmad Masri; Syed Bukhari; Shahzad Ahmad; Ricardo Nieves; Yvonne S Eisele; William Follansbee; Amy Brownell; Timothy C Wong; Erik Schelbert; Prem Soman
Journal:  Circ Cardiovasc Imaging       Date:  2020-02-17       Impact factor: 7.792

6.  Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy.

Authors:  Chiara Gallini; Francesca Tutino; Raffaele Martone; Alfonso Ciaccio; Egidio Natalino Costanzo; Giulia Taborchi; Sofia Morini; Simone Bartolini; Silvia Farsetti; Carlo Di Mario; Federico Perfetto; Francesco Cappelli
Journal:  J Nucl Cardiol       Date:  2019-02-14       Impact factor: 5.952

Review 7.  99m Technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy.

Authors:  Nobuhiro Tahara; Olivier Lairez; Jin Endo; Atsushi Okada; Mitsuharu Ueda; Tomonori Ishii; Yoshinobu Kitano; Hahn-Ey Lee; Eleonora Russo; Toru Kubo
Journal:  ESC Heart Fail       Date:  2021-11-29

8.  Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis.

Authors:  Robert J H Miller; Sebastien Cadet; Darren Mah; Payam Pournazari; Denise Chan; Nowell M Fine; Daniel S Berman; Piotr J Slomka
Journal:  J Nucl Cardiol       Date:  2021-03-10       Impact factor: 5.952

9.  Diagnostic Efficacy of Cardiac Scintigraphy with 99mTc-Pyrophosphate for Latent Myocardial Inflammation in Patients with Atrial Fibrillation.

Authors:  Julia Ilyushenkova; Svetlana Sazonova; Konstantin Zavadovsky; Roman Batalov; Yuliya Rogovskaya; Yana Anfinogenova; Yurii Lishmanov
Journal:  Cardiol Res Pract       Date:  2020-03-16       Impact factor: 1.866

Review 10.  Multi-modality imaging in transthyretin amyloid cardiomyopathy.

Authors:  Bryan Paul Traynor; Aamir Shamsi; Victor Voon
Journal:  World J Cardiol       Date:  2019-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.